雷珠单抗持续给药下糖尿病黄斑水肿的消退过程

Time Course of Resolution of Diabetic Macular Edema by Sustained Suppression of VEGF-A with the Port Delivery Platform with Ranibizumab

Sustained VEGF-A suppression via the Port Delivery System with ranibizumab effectively resolves diabetic macular edema with most patients achieving edema normalization; slow resolution may mimic treatment unresponsiveness, warranting reclassification as slow response.
Real-World Eligibility of Diabetic Macular Edema Patients for Anti-VEGF Trials: Implications for Clinical Practice and Health Equity

Real-World Eligibility of Diabetic Macular Edema Patients for Anti-VEGF Trials: Implications for Clinical Practice and Health Equity

A significant proportion of real-world diabetic macular edema patients are excluded from clinical trials of anti-VEGF therapy due to stringent systemic criteria, disproportionately affecting racial minorities. This study highlights the need for broader inclusion to enhance trial applicability.
FAc Intravitreal Implant Achieves Comparable Visual Outcomes with 53% Fewer Injections in Diabetic Macular Edema: Phase 4 NEW DAY Study

FAc Intravitreal Implant Achieves Comparable Visual Outcomes with 53% Fewer Injections in Diabetic Macular Edema: Phase 4 NEW DAY Study

The Phase 4 NEW DAY study demonstrates that fluocinolone acetonide (FAc) 0.19 mg implant as baseline therapy achieves similar visual acuity and anatomical improvements compared to aflibercept in diabetic macular edema patients, while significantly reducing total injection burden despite not meeting the primary rescue injection endpoint.